

# RSC Applied Interfaces


GOLD  
OPEN  
ACCESS

**Interfacial and surface research  
with an applied focus**

**Interdisciplinary and open access**

**[rsc.li/RSCApplInter](https://rsc.li/RSCApplInter)**

**Fundamental questions  
Elemental answers**



**Showcasing research from Dr Aron Blaesi's group at Enzian Pharmaceuticals, Zurich, Switzerland and Cambridge, MA, USA.**

Enhancing the bioavailability of sparingly-soluble drugs by expandable, solid-solution fibrous dosage forms

At present, the effectiveness of many life-saving oral therapies employing a sparingly water-soluble drug is limited by the drug's bioavailability. For enhancing bioavailability, Blaesi's group at Enzian Pharmaceuticals has developed an expandable, solid-solution fibrous dosage form. The fibrous form releases drug into the stomach at a high rate for prolonged time. In dogs it enhanced the bioavailability of the sparingly-soluble model drug nilotinib three-fold compared with the present crystalline drug particle-filled capsules.

Image reproduced by permission of Aron H Blaesi, Enzian Pharmaceuticals Blaesi AG from *RSC Pharm.*, 2026, **3**, 88.

**As featured in:**



See Aron H. Blaesi *et al.*, *RSC Pharm.*, 2026, **3**, 88.